mrna
broad
potenti
treat
diseas
requir
protein
express
howev
mrna
also
induc
immun
respons
associ
toxic
replac
uridin
base
pseudouridin
postul
modul
mrna
immunogen
potenc
explor
immun
respons
activ
lipid
nanoparticleformul
unmodifi
pseudouridinemodifi
mrna
administ
system
vivo
pseudouridin
modif
mrna
signific
effect
lipid
nanoparticl
physic
properti
protein
express
vivo
mrna
immunogen
compar
unmodifi
mrna
deliv
system
livertarget
lipid
nanoparticl
reduc
vitro
transfect
level
indic
transient
extracellular
innat
immun
respons
mrna
observ
includ
neutrophilia
myeloid
cell
activ
upregul
four
serum
cytokin
studi
provid
insight
immun
respons
mrna
lipid
nanoparticl
suggest
pseudouridin
modif
may
unnecessari
therapeut
applic
mrna
liver
messeng
rna
mrna
deliveri
emerg
attract
strategi
treatment
varieti
diseas
nanoparticl
deliveri
vehicl
includ
lipid
nanoparticl
lnp
polym
nanoparticl
virus
other
develop
tool
encapsul
deliv
rna
cytoplasm
nake
nucleic
acid
readili
cross
cell
membran
vitro
transcrib
ivt
mrna
known
activ
variou
pattern
recognit
receptor
includ
tolllik
receptor
rigi
rnadepend
protein
kinas
pkr
lead
antivir
immun
respons
synthet
base
modif
report
mitig
immunogen
improv
stabil
small
interf
rna
sirna
hypothes
similar
strategi
could
also
prove
benefici
mrna
therapeut
reduc
immunogen
increas
stabil
therapeut
mrna
use
naturallyoccur
base
modif
propos
includ
pseudouridin
n
n
methylpseudouridin
howev
one
disadvantag
basemodifi
mrna
potenti
decreas
translat
capac
mrna
one
common
approach
mrna
base
modif
substitut
uridin
pseudouridin
pseudou
sometim
use
combin
replac
cytidin
cowork
perform
pioneer
work
pseudou
modif
mrna
find
pseudoumodifi
mrna
resist
ribonucleas
rnase
degrad
reduc
activ
tlr
pkr
interestingli
result
improv
translat
efficaci
vitro
vivo
compar
unmodifi
mrna
deliv
liposom
nonliposom
formul
howev
thess
et
al
recent
report
pseudou
modif
significantli
diminish
mrna
translat
codonoptim
unmodifi
mrna
upregul
three
measur
proinflammatori
cytokin
vivo
deliv
intraperiton
lipidpolym
nonliposom
transfect
reagent
hypothes
differ
literatur
report
regard
immunogen
efficaci
pseudoumodifi
mrna
vivo
summar
tabl
may
due
limit
analysi
extracellular
innat
immun
respons
mrna
vivo
use
differ
deliveri
vehicl
methodolog
materi
properti
studi
previous
demonstr
deliveri
materi
properti
dramat
affect
potenc
encapsul
nucleic
acid
pardi
et
al
recent
report
mrnalnp
differ
kinet
efficaci
vivo
depend
rout
administr
effect
pseudou
modif
mrna
immunogen
efficaci
remain
outstand
question
import
implic
therapeut
applic
mrna
therefor
present
work
aim
perform
thorough
analysi
extracellular
innat
immun
respons
efficaci
mrna
without
pseudou
modif
vivo
use
mice
maxim
protein
express
mrna
deliv
intraven
use
lnp
base
lipidlik
materi
recent
studi
therapeut
hemophilia
b
mous
model
result
indic
pseudou
modif
mrna
measur
chang
lnp
physic
properti
neither
improv
efficaci
reduc
immunogen
mrnalnp
deliv
system
furthermor
high
mrna
dose
discov
indic
yetuncharacter
transient
extracellular
innat
immun
respons
intravenouslydeliv
mrnalnp
includ
cytokin
elev
neutrophilia
myeloid
cell
activ
blood
spleen
data
indic
improv
vivo
perform
pseudou
modif
mrna
suggest
unmodifi
mrna
may
least
suitabl
system
mrnalnp
administr
mrna
three
differ
sequenc
synthes
without
pseudouridin
pseudou
replac
uridin
fig
follow
vitro
transcript
ivt
mrna
product
yield
matur
mrna
respect
predict
length
fig
fig
electrophoresi
size
fraction
perform
synthes
mrna
confirm
absenc
smaller
length
fragment
fig
gener
found
ivt
pseudoumodifi
mrna
significantli
lower
yield
typic
half
unmodifi
mrna
tabl
pseudou
extra
hydrogenbond
donor
shown
asterisk
fig
allow
increas
local
rna
stack
thermodynam
favor
duplex
format
rigid
sugarphosph
backbon
observ
pseudoumodifi
mrna
migrat
slightli
lower
observ
molecular
weight
unmodifi
counterpart
bioanalyz
fig
agaros
gel
fig
could
attribut
tighter
pack
thu
smaller
hydrodynam
volum
pseudoumodifi
mrna
howev
differ
mrna
secondari
structur
impart
pseudou
modif
affect
mrna
load
lipid
nanoparticl
lnp
mrna
encapsul
lnp
fig
use
formul
paramet
previous
optim
specif
mrna
deliveri
effect
pseudou
modif
mrna
translat
effici
deliv
lnp
assess
vitro
vivo
studi
mrna
code
two
protein
ie
mrna
differ
length
test
firefli
luciferas
luc
model
nonsecret
luminesc
protein
erythropoietin
epo
secret
serum
protein
therapeut
applic
anemia
hela
cell
vitro
unmodifi
mrnalnp
approxim
twice
potent
pseudoumodifi
mrnalnp
multipl
dose
epoencod
fig
lucencod
fig
mrna
similar
experi
thess
et
al
transfect
hela
cell
mrna
lipoplex
lipofectamin
report
unmodifi
mrna
led
significantli
higher
protein
express
pseudoumodifi
mrna
luc
epo
show
similar
result
across
multipl
dose
vitro
use
lnp
better
serum
stabil
longer
circul
time
less
prone
aggreg
lipoplex
vivo
lnp
formul
either
unmodifi
pseudoumodifi
mrna
next
evalu
efficaci
vivo
follow
system
deliveri
contrast
vitro
find
signific
differ
epo
express
unmodifi
pseudou
epo
mrnaload
lnp
observ
follow
intraven
administr
mice
dose
rang
mgkg
mgkg
fig
knowledg
first
report
pseudou
modif
improv
potenc
mrna
deliv
intraven
lnp
mous
model
similarli
signific
differ
unmodifi
pseudou
luc
mrnaload
lnp
observ
luc
express
spleen
liver
fig
two
organ
measur
luc
express
either
treatment
biodistribut
alter
pseudou
modif
mrna
protein
express
occur
predomin
liver
consist
previou
report
next
object
determin
pseudou
modif
alter
immunogen
mrna
deliv
system
vivo
use
lnp
unmodifi
pseudoumodifi
mrna
scrambl
code
region
length
epo
use
ensur
immunogen
respons
translat
exogen
protein
furthermor
lnp
formul
without
mrna
use
control
pars
immunogen
mrna
lipid
deliveri
materi
previou
studi
investig
immunogen
pseudoumodifi
mrna
limit
measur
small
number
common
proinflammatori
cytokin
vivo
follow
administr
nonlnp
formul
tabl
measur
panel
thirti
cytokin
mous
serum
six
hour
postintraven
inject
mrnalnp
without
pseudou
modif
fig
mrnalnp
inject
intraven
high
dose
observ
vari
degre
elev
level
varieti
interleukin
coloni
stimul
factor
chemokin
six
hour
postinject
rel
control
lnp
without
mrna
upregul
cytokin
gcsf
rant
mig
confirm
depend
dose
mrna
fig
suffici
low
dose
mrna
cytokin
respons
minim
importantli
pseudoumodifi
mrna
substanti
reduc
serum
cytokin
level
compar
unmodifi
mrna
six
hour
postinject
moreov
pseudou
modif
mrna
reduc
mrnalnp
liver
enzym
alanin
transaminas
alt
aspart
transaminas
ast
fig
observ
elev
cytokin
produc
influenc
myeloid
cell
led
us
question
effect
mrnalnp
blood
splenic
immun
cell
distribut
activ
immun
cell
distribut
blood
spleen
therefor
measur
six
hour
postintraven
inject
mrnalnp
suffici
high
dose
mrna
mgkg
observ
neutrophilia
increas
percentag
neutrophil
among
total
immun
cell
blood
fig
spleen
fig
addit
neutrophil
blood
spleen
express
significantli
higher
level
cellsurfac
protein
marker
neutrophil
activ
includ
also
increas
spleen
fig
notabl
neutrophil
level
return
baselin
fig
b
activ
marker
longer
upregul
hour
postinject
fig
suggest
neutrophilia
induc
mrna
administr
transient
respons
correspondingli
small
statist
signific
drop
nonneutrophil
myeloid
cell
observ
hour
postintraven
administr
mrnalnp
fig
b
return
baselin
hour
postinject
fig
b
spleen
dendrit
cell
macrophag
express
higher
level
activ
marker
marker
mhcii
hour
postinject
fig
return
baselin
hour
postinject
fig
similar
increas
express
observ
bone
marrowderiv
dendrit
cell
follow
lipoplex
antigenencod
mrna
administ
subcutan
mice
pollard
et
al
hour
spleen
mass
increas
unmodifi
pseudoumodifi
mrnalnp
fig
differ
observ
hour
postinject
compar
vehicleinject
pbsinject
mice
promin
studi
unmodifi
pseudoumodifi
mrnalnp
administr
result
similar
chang
myeloid
cell
distribut
activ
suggest
pseudou
modif
reduc
immun
activ
mrna
deliv
system
lnp
broad
use
mrna
clinic
requir
develop
safe
effect
deliveri
system
one
method
vari
mrna
potenc
immunogen
rna
base
modif
pseudouridin
pseudou
replac
uridin
fig
commonli
report
system
use
mrna
requir
deliveri
vehicl
ensur
cellular
uptak
target
specif
tissuescel
type
prevent
mrna
degrad
recent
lnp
demonstr
effici
mrna
deliveri
vehicl
studi
vivo
therapeut
context
find
demonstr
properti
mrnaload
lnp
specif
encapsul
effici
diamet
morphologydo
chang
result
pseudou
modif
mrna
payload
fig
spite
differ
secondari
structur
impart
pseudoumodif
mrna
literatur
contain
differ
effect
pseudou
modif
mrna
immunogen
potenc
deliv
use
nanoparticl
vehicl
colleagu
report
pseudou
modif
increas
efficaci
intravenouslyadminist
spleentarget
lipofectincomplex
mrna
intraperitoneallyadminist
spleentarget
transitcomplex
commerci
nonliposom
lipidpolym
transfect
reagent
mrna
thess
et
al
report
pseudou
modif
decreas
efficaci
intraperitoneallyadminist
codonoptim
mrna
deliv
transit
shown
tabl
hypothes
differ
effect
pseudou
modif
result
combin
four
variabl
differ
experimenttoexperi
deliveri
materi
lnp
vs
liposom
vs
nonliposom
lipidpolym
reagent
rout
administr
intraven
vs
intraperiton
transfect
cell
type
liver
vs
spleen
mrna
properti
differ
utr
codonoptim
hplcpurifi
experi
chose
deliveri
materi
lnp
rout
administr
intraven
clinic
potenti
rel
high
protein
express
per
dose
mrna
use
condit
sought
evalu
effect
pseudou
mrna
modif
efficaci
use
two
differ
mrna
sequenc
vitro
fig
vivo
fig
result
indic
pseudou
modifi
unmodifi
mrna
similar
efficaci
deliv
intraven
use
lnp
wildtyp
mice
interestingli
pseudou
mrnalnp
result
significantli
lower
translat
vitro
hela
cell
vitro
experi
fulli
recapitul
complex
vivo
environ
previou
studi
found
efficaci
sirnalnp
vitro
alway
correl
efficaci
found
vivo
case
mrnalnp
increas
resist
impart
pseudou
modif
mrna
degrad
may
signific
vivo
perhap
hela
cell
hepatocyt
process
pseudoumodifi
mrna
differ
addit
increas
level
cytokin
includ
rant
gcsf
mig
fig
observ
follow
administr
high
dose
unmodifi
pseudoumodifi
mrnalnp
elev
cytokin
previous
implic
innat
immun
respons
foreign
nucleic
acid
human
fetal
membran
viral
ssrna
found
upregul
rant
gcsf
among
cytokin
mig
test
addit
report
mig
rant
significantli
elev
follow
mrna
transfect
cell
vitro
rant
secret
cell
appear
significantli
differ
lipoplex
unmodifi
pseudou
mrna
four
cytokin
involv
neutrophil
recruit
function
gcsf
control
neutrophil
prolifer
differenti
traffick
three
rant
mig
inflammatori
chemokin
typic
signal
recruit
myeloid
cell
neutrophil
site
inflamm
infect
inde
neutrophilia
neutrophil
activ
also
observ
respons
unmodifi
pseudoumodifi
mrnalnp
hour
postinject
fig
neutrophilia
inflammatori
cytokin
respons
commonli
observ
part
innat
immun
respons
rnabas
viral
infecti
agent
mrnaload
lipid
nanoparticl
share
sever
structur
similar
type
ssrna
virus
like
mrnalnp
ssrna
virus
spheric
morpholog
diamet
order
nm
singlestrand
rna
decor
outsid
particl
cytokin
product
neutrophilia
observ
respons
ssrna
virus
includ
west
nile
viru
sar
hantaviru
activ
receptor
recogn
pathogenassoci
damageassoci
molecular
pattern
data
suggest
regardless
pseudou
modif
innat
immun
system
may
interpret
mrnaladen
lnp
high
enough
dose
similar
molecular
pattern
recognit
mechan
howev
import
observ
respons
hyperacut
observ
hour
postinject
transient
return
baselin
hour
find
provid
addit
perspect
exist
literatur
tabl
provid
comprehens
descript
vivo
extracellular
innat
immun
respons
mrnaload
lnp
result
suggest
intravenouslyinject
mrnalnp
interact
phagocyt
myeloid
cell
bloodstream
neutrophil
specif
activ
secret
sever
cytokin
circul
neutrophil
also
observ
higher
percentag
activ
spleen
postul
either
activ
neutrophil
blood
monocyt
interact
mrnalnp
activ
dendrit
cell
macrophag
spleen
moreov
encapsul
mrna
express
predomin
liver
express
occur
spleen
fig
independ
conclus
base
mrna
modif
result
contribut
mechanist
insight
natur
innat
immun
respons
elicit
therapeut
mrna
circul
model
suggest
potenti
approach
reduc
immun
respons
decreas
blood
concentr
mrnalnp
therebi
minim
interact
circul
myeloid
cell
exampl
may
possibl
mediat
effect
gradual
intraven
drip
mrnalnp
rather
bolu
infus
given
lnp
encapsul
protect
unmodifi
mrna
rnase
degrad
fig
stabil
impart
pseudou
modif
circul
rnase
bloodstream
may
unnecessari
mrna
deliv
lnp
also
noteworthi
incorpor
pseudou
mrna
significantli
reduc
ivt
yield
tabl
pseudou
triphosph
current
much
expens
uridin
triphosph
obtain
commerci
small
scale
result
suggest
pseudou
modif
improv
efficaci
alter
immunogen
vivo
indic
unmodifi
mrna
may
prefer
futur
applic
requir
system
deliveri
mrnalnp
futur
work
necessari
determin
mrna
base
modif
fact
improv
efficaci
alter
immunogen
mrna
deliv
system
lnp
exampl
n
methylpseudouridin
recent
report
result
significantli
higher
translat
vivo
compar
unmodifi
mrna
deliv
lipofectaminemrna
complex
via
intramuscular
intraderm
administr
howev
remain
seen
result
chang
differ
deliveri
vehicl
administr
rout
mrna
properti
list
tabl
certain
therapeut
applic
mrnabas
vaccin
immun
respons
mrnalnp
may
desir
applic
inappropri
immun
respons
could
result
unwant
toxic
immun
respons
observ
measur
transient
natur
nearli
marker
immunogen
return
baselin
level
hour
addit
transient
neutrophilia
sign
infect
necessarili
harm
signific
increas
neutrophil
count
also
observ
vigor
exercis
pregnanc
furthermor
low
dose
mrnalnp
mgkg
signific
immun
respons
observ
conclus
evalu
pseudoumodifi
unmodifi
mrna
encapsul
lnp
measur
nanoparticl
physic
properti
vitro
vivo
potenc
vivo
immunogen
pseudou
modif
mrna
result
chang
lnp
size
morpholog
encapsul
effici
furthermor
pseudou
modif
mrna
improv
efficaci
mrnalnp
vitro
vivo
lastli
identifi
three
previouslyunreport
indic
modest
transient
extracellular
innat
immun
respons
mrnalnp
myeloid
cell
activ
neutrophilia
cytokin
elev
determin
pseudou
modif
mrna
reduc
immun
respons
report
benefit
studi
use
pseudoumodifi
mrna
deliv
system
lipid
nanoparticl
dna
plasmid
invitrogen
contain
promot
upstream
sequenc
luciferas
luc
erythropoietin
epo
scrambl
epo
code
region
scrambl
mrna
use
templat
mrna
synthesi
dna
plasmid
linear
use
restrict
enzym
xbai
new
england
biolab
ipswich
transcrib
use
hiscrib
rna
synthesi
kit
new
england
biolab
make
pseudouridinemodifi
mrna
uridin
triphosph
replac
pseudouridin
triphosph
trilink
san
diego
ca
transcript
step
mrna
cap
vaccinia
cap
system
new
england
biolab
cap
modifi
use
mrna
cap
new
england
biolab
polya
tail
ad
rna
use
poli
polymeras
kit
new
england
biolab
mrna
purifi
transcript
tail
step
use
megaclear
rna
purif
column
life
technolog
beverli
concentr
determin
use
nanodrop
thermo
scientif
cambridg
final
purifi
mrna
contain
cap
utr
consist
partial
sequenc
cytomegaloviru
cmv
immedi
earli
gene
code
region
describ
utr
consist
partial
sequenc
human
growth
hormon
hgh
gene
polya
tail
estim
approxim
nucleotid
long
nt
use
gener
standard
curv
convert
bioanalyz
result
migrat
time
number
base
lipid
nanoparticl
lnp
prepar
previous
describ
mrna
encapsul
effici
ie
load
effici
calcul
perform
modifi
quantit
ribogreen
rna
assay
invitrogen
previous
describ
diamet
polydispers
pdi
lnp
measur
use
dynam
light
scatter
zetap
brookhaven
instrument
diamet
report
largest
intens
mean
peak
averag
lnp
prepar
cryogen
transmiss
electron
microscopi
cryotem
dialyz
pb
deposit
onto
lacey
copper
grid
coat
continu
carbon
film
cool
continu
liquid
nitrogen
use
minimum
dose
method
imag
perform
use
jeol
feg
microscop
jeol
freis
germani
oper
kv
magnif
set
rnase
thermofish
incub
mrna
mrnalnp
mu
mrna
buffer
made
mm
trishcl
mm
edta
nacl
room
temperatur
min
rnase
inactiv
ad
mu
proteinas
k
mrna
incub
min
extract
mrna
lnp
equal
volum
phenolchloroform
ad
tube
vortex
vigor
aqueou
phase
contain
mrna
extract
mrna
character
use
egel
ex
gel
previous
describ
hela
cell
atcc
manassa
va
cultur
high
glucos
dulbecco
modifi
eagl
medium
thermofish
contain
fetal
bovin
serum
penicillinstreptomycin
maintain
co
transfect
experi
cell
plate
cellswel
plate
hr
media
well
replac
media
contain
lnp
anoth
hr
assay
perform
describ
well
contain
epo
mrnalnp
supernat
remov
measur
epo
concentr
use
elisa
assay
human
erythropoietin
quantikin
ivd
elisa
kit
r
system
minneapoli
md
live
cell
number
quantifi
use
multitoxfluor
multiplex
cytotox
assay
promega
madison
wi
well
contain
luc
mrnalnp
live
cell
number
first
quantifi
use
multitoxfluor
multiplex
cytotox
assay
luminesc
measur
use
brightglo
luciferas
assay
system
promega
assay
perform
accord
manufactur
guidelin
luminescencefluoresc
measur
use
tecan
infinit
pro
micropl
reader
anim
studi
approv
determin
luciferas
level
mice
administ
intraperiton
inject
dluciferin
mgml
pb
min
mice
sacrif
organ
collect
organ
luminesc
measur
use
ivi
imag
system
perkinelm
waltham
quantifi
use
livingimag
softwar
perkinelm
prepar
blood
singl
cell
suspens
blood
mix
ml
rbc
lysi
buffer
incub
ice
min
prepar
spleen
singl
cell
suspens
spleen
harvest
mice
follow
euthanasia
manual
ground
forcep
pb
pass
filter
follow
centrifug
remov
supernat
cell
resuspend
ml
rbc
lysi
buffer
incub
min
singl
cell
suspens
made
cell
fix
paraformaldehyd
flow
buffer
pb
contain
bsa
mm
edta
min
follow
identif
cell
popul
use
cell
b
cell
neutrophil
nonneutrophil
myeloid
macrophag
dendrit
cell
compar
two
group
student
test
use
assum
gaussian
distribut
unequ
varianc
perform
multipl
test
two
group
eg
dose
respons
cytokin
multipl
comparison
correct
use
method
mous
studi
data
present
repres
one
independ
experi
statist
signific
defin
alpha
level
statist
analys
perform
use
graphpad
prism
softwar
refer
web
version
pubm
central
supplementari
materi
hypothes
extracellular
innat
immun
respons
mrnalnp
inject
system
regardless
pseudou
modif
mrna
